Cargando…
Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
Insulin like growth factor receptor (IGF-1R) targeting became one of the most investigated areas in anticancer drug development during the last decade. Strategies aiming to block IGF-1R activity include monoclonal antibodies, tyrosine kinase inhibitors and anti-ligands antibodies. Initial enthusiasm...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484277/ https://www.ncbi.nlm.nih.gov/pubmed/22415797 http://dx.doi.org/10.1007/s10637-012-9811-0 |